PT  - JOURNAL ARTICLE
AU  - I Zemni
AU  - H Mansouri
AU  - I Ben Safta
AU  - N Boujelbene
AU  - J Ben Hassouna
AU  - M Hechiche
AU  - R Chargui
AU  - K Rahal
TI  - 288 What is the prognostic value of lymphadenectomy in advanced epithelial ovarian cancer?
AID  - 10.1136/ijgc-2019-IGCS.288
DP  - 2019 Sep 01
TA  - International Journal of Gynecologic Cancer
PG  - A120--A121
VI  - 29
IP  - Suppl 3
4099  - http://ijgc.bmj.com/content/29/Suppl_3/A120.3.short
4100  - http://ijgc.bmj.com/content/29/Suppl_3/A120.3.full
SO  - Int J Gynecol Cancer2019 Sep 01; 29
AB  - Objectives To evaluate the role of lymphadenectomy in advanced epithelial ovarian cancer (EOC).Methods Data of 121 patients who underwent surgery for FIGO staged IIB-IV EOC between 2000 and 2010 were retrospectively reviewed.Results Primary debulking surgery was performed in 96 patients and interval debulking surgery in 25 cases. Maximal cytoreduction (R0) was achieved in 37 of patients (30.6%), 39 patients had a residual disease ≤1 cm (32.2%) and 45 had a residual disease <1 cm (37.2%). Lymphadenectomy was performed in 60 patients (50.4%). The 5 years OS and RFS were significantly correlated to the tumor stage, maximal cytoreduction, LN status (table1) and lymphadenectomy was an independent prognostic factor of OS (HR=1.696, 95% CI=1.025–2.807, p=0.04) and RFS (HR=2.162, 95% CI=1.334–3.504, p=0.002) with a higher survival rates in case of associated pelvic lymphadenectomy (PL) and para aortic lymphadenectomy (PAL). The 5 years RFS of patients with a residual disease of more than 1 cm was not significantly improved by lymphadenectomy (7.1% vs 24.2%, p=0.196) despite the gain in term of OS (7.2% vs 42.7%, p=0.006).View this table:Abstract 288 Table 1 Conclusions Lymphadenectomy is associated with a better survival in patients with advanced ovarian cancer.